** Shares of drug developer Monte Rosa Therapeutics rise 37.22% to $6.84 ** Novartis will pay GLUE $150 million upfront for a global license to develop, manufacture and sell some drug candidates
** GLUE will also be eligible for future payments of up to $2.1 billion in development, regulatory, and sales milestones
** The agreement is expected to accelerate the development of MRT-6160, which is in an early-stage study for immune-mediated conditions
** GLUE stock up ~20% YTD
(Reporting by Sriparna Roy in Bengaluru) ((mailto:Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。